Non-myeloablative conditioning before allogeneic stem cell transplantation in adult acute lymphoblastic leukemia

Haematologica

Volumn 88, Issue 5, 2003, Pages 484-486

  Gökbuget, Nicola ^a   Hoelzer, Dieter ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; CANCER REGRESSION; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HUMAN; MINIMAL RESIDUAL DISEASE; NOTE; PROGNOSIS; STEM CELL TRANSPLANTATION; TREATMENT INDICATION; WHOLE BODY RADIATION;

ADULT; CLINICAL TRIALS; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; RECURRENCE; TRANSPLANTATION CONDITIONING;

EID: 0038777313     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (20)

1. Hoelzer D, Gökbuget N. New approaches in acute lymphoblastic leukemia in adults: where do we go? Semin Oncol 2000;27:540-59.
2. Arnold R, Bunjes D, Ehninger G. Allogeneic stem cell transplantation from HLA-identical sibling donor in high risk ALL patients is less effective than transplantation from unrelated donors. Blood 2002;100:77a[abstract 279].
3. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998;91:756-63.
4. Laport GG. Nonmyeloablative allogeneic stem cell transplantation for acute leukemia. Curr Hematol Rep 2003;2:49-56.
5. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555-62.
6. Passweg JR, Tiberghien P, Cahn JY, Vowels MR, Camitta BM, Gale RP, et al. Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia. Bone Marrow Transplant 1998;21:153-8.
7. Uzunel M, Mattsson J, Jaksch M, Remberger M, Ringden O. The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia. Blood 2001;98:1982-4.
8. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001;97:631-7.
9. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versustumor effects. Blood 2001;97:3390-400.
10. Corradini P, Tarella C, Olivieri A, Gianni AM, Voena C, Zallio F, et al. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood 2002;99:75-82.
11. Bornhauser M, Thiede C, Platzbecker U, Jenke A, Helwig A, Plettig R, et al. Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients. Clin Cancer Res 2001;7:2254-62.
12. Pawson R, Potter MN, Theocharous P, Lawler M, Garg M, Yin JA, et al. Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +/- Ida) and second allogeneic stem cell transplant. Br J Haematol 2001;115:622-9.
13. Martino R, Caballero MD, Canals C, Simon JA, Solano C, Urbano-Ispizua A, et al. Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study. ALLOPBSCT Subcommittee of the Spanish Group for Haematopoietic Transplantation (GETH). Group GEL-TAMO. Br J Haematol 2001; 115:653-9.
14. Rezvani K, Lalancette M, Szydlo R. Non-myeloablative stem cell transplant (NMSCT) in AML, ALL, and MDS: disappointing outcome for patients with advanced phase disease. Blood 2000;96:479a[abstract].
15. Michallet M, Bilger K, Garban F, Attal M, Huyn A, Blaise D, et al. Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and posttransplantation factors on outcome. J Clin Oncol 2001;19:3340-9.
16. Arnold R, Massenkeil G, Bornhauser M, Ehninger G, Beelen DW, Fauser AA, et al. Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease. Leukemia 2002;16:2423-8.
17. Ruiz-Arguelles GJ, Gomez-Almaguer D, Ruiz-Arguelles A, Gonzalez-Llano O, Cantu OG, Jaime-Perez JC. Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens. Am J Hematol 2001;66:241-4.
18. Martino R, Giralt S, Dolores Caballero M, Mackinnon S, Corradini P, Fernández-Avilés F, et al. Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study. Haematologica 2003;88:561-6.
19. Vindelov L. Allogeneic bone marrow transplantation with reduced conditioning (RC- BMT). Eur J Haematol 2001;66: 73-82.
20. Childs R, Baceci E, Eniaffe R. Older patient age remains a risk factor for transplant related mortality following nonmyeloablative allogeneic stem cell transplantation. Blood 2000; 96:520a [abstract].